Abstract:The synthetic compound 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24) is a potent analog of curcumin that exhibits enhanced biological activity and bioavailability without increasing toxicity. EF24 exerts antitumor activity by arresting the cell cycle and inducing apoptosis, suppressing many types of cancer cells in vitro. The antiproliferative and antiangiogenic properties of EF24 provide theoretical support for its development and application to liver cancers. We investigated the in vitro and in vivo activities of EF24 on liver cancer to better understand its therapeutic effects and mechanisms. EF24 induced significant apoptosis and G2/M-phase cell cycle arrest in mouse liver cancer cell lines, Hepa1-6 and H22. The expression levels of G2/M cell cycle regulating factors, cyclin B1 and Cdc2, were significantly decreased, pp53, p53, and p21 were significantly increased in EF24-treated cells. In addition, EF24 treatment significantly reduced Bcl-2 concomitant with an increase in Bax, enhanced the release of cytochrome c from the mitochondria into the cytosol, resulting in an upregulation of cleaved-caspase-3, which promoted poly (ADP-ribose) polymerase cleavage. EF24-treated cells also displayed decreases in phosphorylated Akt, phosphorylated extracellular signal-regulated kinase and vascular endothelial growth factor. Our in vitro protein expression data were confirmed in vivo using a subcutaneous hepatocellular carcinoma (HCC) tumor model. This mouse HCC model confirmed that total body weight was unchanged following EF24 treatment, although tumor weight was significantly decreased. Using an orthotopic HCC model, EF24 significantly reduced the liver/body weight ratio and relative tumor areas compared to the control group. In situ detection of apoptotic cells and quantification of Ki-67, a biomarker of cell proliferation, all indicated significant tumor suppression with EF24 treatment. These results suggest that EF24 exhibits anti-tumor activity on liver cancer cells via mitochondria-dependent apoptosis and inducing cell cycle arrest coupled with antiangiogenesis. The demonstrated activities of EF24 support its further evaluation as a treatment for human liver cancers.

Design, Synthesis, and Evaluation of Asymmetric EF24 Analogues As Potential Anti-Cancer Agents for Lung Cancer.

Design and Optimize N-substituted EF24 as Effective and Low Toxicity NF-κB Inhibitor for Lung Cancer Therapy via Apoptosis-to-Pyroptosis Switch.

The Curcumin Analog EF24 Targets NF-κB and miRNA-21, and Has Potent Anticancer Activity In Vitro and In Vivo

EF24 Inhibits Tumor Growth and Metastasis Via Suppressing NF-kappaB Dependent Pathways in Human Cholangiocarcinoma

Design, Synthesis, and Biological Study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines As EGFR Inhibitors Exerting Cytotoxicities Both under Normoxia and Hypoxia.

Antitumor Agents 295. E-ring Hydroxylated Antofine and Cryptopleurine Analogues As Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis and Biological Evaluation of Novel 4-Phenylaminobenzofuro [2,3-D]pyrimidine Derivatives

Design, Synthesis and Biological Evaluation of Novel 2,4-Diaryl Pyrimidine Derivatives As Selective EGFRL858R/T790M Inhibitors.

Discovery of Antitumor Ursolic Acid Long-Chain Diamine Derivatives As Potent Inhibitors of NF-κB.

A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways

In Vivo and in Vitro Suppression of Hepatocellular Carcinoma by EF24, a Curcumin Analog

Design, Synthesis and Pharmacological Evaluation of N4,N6-disubstituted Pyrimidine-4,6-diamine Derivatives As Potent EGFR Inhibitors in Non-Small Cell Lung Cancer

Novel Hybrids of (phenylsulfonyl)furoxan and Anilinopyrimidine As Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer

Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions

Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non-small cell lung cancer

Synthesis and Biological Evaluation of Indole-2-carbohydrazide Derivatives As Anticancer Agents with Anti-angiogenic and Antiproliferative Activities.

Synthesis and Biological Evaluation of Novel Furopyridone Derivatives as Potent Cytotoxic Agents against Esophageal Cancer

Antitumor Activity Of A New N-Substituted Thiourea Derivative, An Egfr Signaling-Targeted Inhibitor Against A Panel Of Human Lung Cancer Cell Lines

Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents

A potential anticancer agent 1,2-di(quinazolin-4-yl)diselane induces apoptosis in non-small-cell lung cancer A549 cells